Disease · MONDO_0041052

postherpetic neuralgia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. postherpetic neuralgia. Diseases, record MONDO_0041052. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0041052

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: postherpetic neuralgia; Open Targets
Open Targets ID: MONDO_0041052; Open Targets
Orphanet: ORPHA:466673; Orphanet
Highest stage of its drugs: Approval, for 2 of its 53 drugs, from PMDA and TTD; Open Targets

Drugs53

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREGABALIN	CHEMBL1059	Small molecule	Approval	PMDA	17	16	16	Drugs and targets
VARICELLA-ZOSTER IMMUNE GLOBULIN	CHEMBL2108828		Approval	TTD	1	0	0	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
CAPSAICIN	CHEMBL294199	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
GABAPENTIN	CHEMBL940	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
MIROGABALIN	CHEMBL3545125	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BUPIVACAINE	CHEMBL1098	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CRISUGABALIN	CHEMBL5314958	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METHADONE	CHEMBL651	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 53

See all 53 drugs

Targets59

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	6	Voltage-gated N-type calcium channel alpha-1B subunit blocker; Voltage-gated calcium channel modulator	Approval	https://conductscience.org/library/genes/774	Drugs and targets
SCN4A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
SCN10A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN5A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6334	Drugs and targets

1 to 10 of 59

See all 59 targets

Trials85

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01270828	Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia	Phase 3	806	2016-01-13	Post Herpetic Neuralgia	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT02318719	DS-5565 Phase III Study for Post-herpetic Neuralgia	Not applicable	765	2020-11-02	Post-Herpetic Neuralgia	MIROGABALIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00636636	Safety and Efficacy of Gabapentin in Postherpetic Neuralgia	Phase 3	452	2012-01-13	Neuralgia,Postherpetic	GABAPENTIN	Its record names the disease	ClinicalTrials.gov
NCT00394901	A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia	Phase 3	372	2009-02-27	Neuralgia, Postherpetic	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00475904	A Comparison of EpiCept™ NP-1 Topical Cream vs. Oral Gabapentin in Postherpetic Neuralgia (PHN)	Phase 2	360	2011-07-06	Post Herpetic Neuralgia, PHN, Neuropathy, Nerve Pain	AMITRIPTYLINE, GABAPENTIN, KETAMINE	Its record names the disease	ClinicalTrials.gov
NCT02365636	A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)	Phase 2	300	2018-10-23	Postherpetic Neuralgia	FUNAPIDE	Its record names the disease	ClinicalTrials.gov
NCT01129531	A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia	Phase 2	294	2013-11-15	Neuralgia, Postherpetic	SENREBOTASE	Its record names the disease	ClinicalTrials.gov
NCT01678924	A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia	Phase 2	280	2020-01-07	Neuralgia, Postherpetic	SENREBOTASE	Its record names the disease	ClinicalTrials.gov
NCT01455428	Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)	Phase 4	223	2015-05-22	Postherpetic Neuralgia ( PHN )	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT03297294	Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)	Phase 2	142	2020-06-04	Painful Diabetic Neuropathy	OLODANRIGAN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 85

See all 85 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
G-ER vs Placebo: serious adverse events	4 of 221	6 of 231	452	NCT00636636	Trial comparisons
G-ER vs Placebo: Patient Global Impression of Change (PGIC)	94 of 220	77 of 230	450	NCT00636636	Trial comparisons
G-ER vs Placebo: Clinical Global Impression of Change (CGIC)	97 of 220	78 of 230	450	NCT00636636	Trial comparisons
Pregabalin CR DB vs Placebo DB: Participants With Secondary LTR Based on 5 Day Rolling Average Diary Results	49 of 208	87 of 205	413	NCT01270828	Trial comparisons
Pregabalin CR DB vs Placebo DB: Number of Participants With Loss of Therapeutic Response.	29 of 208	63 of 205	413	NCT01270828	Trial comparisons
Pregabalin vs Placebo: serious adverse events	2 of 111	0 of 109	220	NCT01455428	Trial comparisons
XPF-002 vs Placebo: serious adverse events	1 of 62	1 of 63	125	NCT01195636	Trial comparisons
GEn 1200 mg vs GEn 3600 mg: Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) at the Last Week of Each Treatment Period Using LOCF Data	17 of 63	28 of 61	124	NCT00617461	Trial comparisons
XPF-002 vs Placebo: Proportion of Subjects Using Rescue Analgesic Medications During XPF-002 Treatment Compared to Placebo Treatment	38 of 57	40 of 57	114	NCT01195636	Trial comparisons
XPF-002 vs Placebo: Proportion of Subjects Achieving 50% Improvement in Mean Daily Pain Score From Baseline to Week 3 on XPF-002 Treatment Compared to Placebo Treatment	15 of 52	6 of 52	104	NCT01195636	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials37

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
22769236	RESULT	1	PubMed
19485723	RESULT	1	PubMed
19480610	RESULT	1	PubMed
19432499	RESULT	1	PubMed
19366301	RESULT	1	PubMed
19301937	RESULT	1	PubMed
16466610	RESULT	1	PubMed
41199896	DERIVED	1	PubMed
40950954	DERIVED	1	PubMed
39320907	DERIVED	1	PubMed

1 to 10 of 37

See all 37 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0041052

GET https://conductscience.org/api/diseases/v1/MONDO_0041052/drugs?page=2

API reference For AI assistants